These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 35464283)

  • 21. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.
    Kudo M; Aoki T; Ueshima K; Tsuchiya K; Morita M; Chishina H; Takita M; Hagiwara S; Minami Y; Ida H; Nishida N; Ogawa C; Tomonari T; Nakamura N; Kuroda H; Takebe A; Takeyama Y; Hidaka M; Eguchi S; Chan SL; Kurosaki M; Izumi N
    Liver Cancer; 2023 Sep; 12(4):321-338. PubMed ID: 37901197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
    Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
    J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
    Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
    BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?
    Jiang C; Sun XD; Qiu W; Chen YG; Sun DW; Lv GY
    Hepatobiliary Pancreat Dis Int; 2023 Feb; 22(1):7-13. PubMed ID: 36825482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements.
    Sun Y; Zhang W; Bi X; Yang Z; Tang Y; Jiang L; Bi F; Chen M; Cheng S; Chi Y; Han Y; Huang J; Huang Z; Ji Y; Jia L; Jiang Z; Jin J; Jin Z; Li X; Li Z; Liang J; Liu L; Liu Y; Lu Y; Lu S; Meng Q; Niu Z; Pan H; Qin S; Qu W; Shao G; Shen F; Song T; Song Y; Tao K; Tian A; Wang J; Wang W; Wang Z; Wu L; Xia F; Xing B; Xu J; Xue H; Yan D; Yang L; Ying J; Yun J; Zeng Z; Zhang X; Zhang Y; Zhang Y; Zhao J; Zhou J; Zhu X; Zou Y; Dong J; Fan J; Lau WY; Sun Y; Yu J; Zhao H; Zhou A; Cai J
    Liver Cancer; 2022 Jun; 11(3):192-208. PubMed ID: 35949289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From Conversion to Resection for Unresectable Hepatocellular Carcinoma: A Review of the Latest Strategies.
    Liang C; He Z; Tao Q; Tang X; Jiang L; Tu X; Liu Z; Chen H; Xie F; Zheng Y
    J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study.
    Zhang J; Zhang X; Mu H; Yu G; Xing W; Wang L; Zhang T
    Front Oncol; 2021; 11():729764. PubMed ID: 34868921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements.
    Kudo M; Han KH; Ye SL; Zhou J; Huang YH; Lin SM; Wang CK; Ikeda M; Chan SL; Choo SP; Miyayama S; Cheng AL
    Liver Cancer; 2020 Jun; 9(3):245-260. PubMed ID: 32647629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada.
    Wong JK; Lim HJ; Tam VC; Burak KW; Dawson LA; Chaudhury P; Abraham RJ; Meyers BM; Sapisochin G; Valenti D; Samimi S; Ramjeesingh R; Mujoomdar A; Martins I; Dixon E; Segedi M; Liu DM
    Cancer Treat Rev; 2023 Apr; 115():102526. PubMed ID: 36924644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review.
    Tang H; Cao Y; Jian Y; Li X; Li J; Zhang W; Wan T; Liu Z; Tang W; Lu S
    Biosci Trends; 2022 May; 16(2):130-141. PubMed ID: 35431288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
    Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.
    Poon RT; Fan ST; Tsang FH; Wong J
    Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports.
    Tomonari T; Sato Y; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Okamoto K; Miyamoto H; Muguruma N; Saito Y; Imura S; Bando Y; Shimada M; Takayama T
    Medicine (Baltimore); 2020 Oct; 99(42):e22782. PubMed ID: 33080748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.
    Zhu XD; Huang C; Shen YH; Ji Y; Ge NL; Qu XD; Chen L; Shi WK; Li ML; Zhu JJ; Tan CJ; Tang ZY; Zhou J; Fan J; Sun HC
    Liver Cancer; 2021 Jul; 10(4):320-329. PubMed ID: 34414120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia.
    Liu DM; Leung TW; Chow PK; Ng DC; Lee RC; Kim YH; Mao Y; Cheng YF; Teng GJ; Lau WY
    Int J Surg; 2022 Jun; 102():106094. PubMed ID: 35662438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis.
    Chen X; Lai L; Ye J; Li L
    Front Oncol; 2021; 11():740762. PubMed ID: 34868936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
    Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
    EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.
    Han KH; Kudo M; Ye SL; Choi JY; Poon RT; Seong J; Park JW; Ichida T; Chung JW; Chow P; Cheng AL
    Oncology; 2011; 81 Suppl 1():158-64. PubMed ID: 22212951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.